For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

BPC-157 + TB-500 + KPV

Also known as: Triple healing blend, BPC-157/TB-500/KPV

Research use only · not FDA-approved

Three-way pre-mixed blend combining two tissue-repair peptides with an anti-inflammatory tripeptide. BPC-157 is a synthetic pentadecapeptide studied in animals for tendon, ligament, and GI healing via angiogenesis (VEGFR2). TB-500 is a synthetic fragment of Thymosin beta-4 that promotes actin regulation, cell migration, and angiogenesis in tissue-repair models. KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH and acts as an NF-kB-inhibiting anti-inflammatory. None of the three components is FDA-approved for human therapeutic use, and there are no controlled human efficacy or safety trials for this specific three-component combination; the rationale is inferred from individual grey-market research peptides.

Where to buy · live market data

Who's worth your money for BPC-157 + TB-500 + KPV

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

No sellers for BPC-157 + TB-500 + KPV are indexed yet — we add vendors and their prices as we find them.

Watch BPC-157 + TB-500 + KPV

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About BPC-157 + TB-500 + KPV

CAS

Molecular formula

Typical dose range

Vendor-dependent; component norms: BPC-157 250-500 mcg/day subcutaneous; TB-500 2-5 mg/week subcutaneous; KPV 200-500 mcg/day. No validated combination dosing exists.

Half-life

BPC-157: disputed (under 30 minutes per most data); TB-500: ~2 hours plasma; KPV: short and not well characterized in humans

Common research uses

musculoskeletal and soft-tissue injury recovery (research only)combined tissue repair plus inflammation control (research only)post-injury recovery stacking (research only)

Safety notes

Not FDA-approved for human therapeutic use; sold as a research-only / grey-market blend. No combination-specific human safety data; risks are extrapolated from limited research on the individual components. Not evaluated by WADA as a blend.

Reconstitution

Reconstitute lyophilized powder with bacteriostatic water; refrigerate after reconstitution.

Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.